Author:
Anastassakis Konstantinos
Publisher
Springer International Publishing
Reference44 articles.
1. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 1991;109(11):1564–8.
2. Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballea S. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol. 2003;13(Suppl 4):S30–43.
3. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the proctor lecture. Invest Ophthalmol Vis Sci. 2001;42(6):1134–45.
4. Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996;7(2):11–7.
5. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Cell signaling. In: Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD, editors. Molecular biology of the cell. 3rd ed. New York: Garland Publishing Inc.; 1994. p. 734–58.